Skip to main content
For doctors
Phase 3 Readout ReportedRare & Orphan Diseases

Delpacibart Etedesiran (del-desiran), HARBOR

Myotonic dystrophy type 1

Sponsor: Novartis

  • N/AEnrollment target
  • N/ATrial sites
  • N/ACountries
  • TBDEst. completion
  • N/ARegistry record

About this trial

Lead antibody-oligonucleotide conjugate from the Avidity Biosciences acquisition.

Primary endpoints

  • Video hand-opening time

Latest update

September 2026

Novartis said the Phase 3 HARBOR study did not meet its primary endpoint in myotonic dystrophy type 1 — the second Phase 3 miss in five days and a setback for the lead asset of its roughly $12 billion Avidity acquisition. It was the clearest 2026 test of the antibody-oligonucleotide-conjugate modality.

Source

Trial information is compiled from public sources and may be out of date. It is not medical advice and is not an offer of enrolment; check the registry entry or speak to a physician before acting on it.